about
Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malariaA phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsIntramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled TrialPopulation structure of Staphylococcus aureus from remote African Babongo PygmiesShort report: Piloting paperless data entry for clinical research in Africa.A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study.Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.The risk to import ESBL-producing Enterobacteriaceae and Staphylococcus aureus through chicken meat trade in GabonShort-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon.Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central AfricaHigh prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese childrenSevere malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.CD4+CD25hiFOXP3+ Regulatory T Cells and Cytokine Responses in Human Schistosomiasis before and after Treatment with PraziquantelRandomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malariaThe use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel.Impact of increasing consultation fees on malaria in Africa.Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.A pilot study on cytotoxic T lymphocyte-4 gene polymorphisms in urinary schistosomiasisSocio-economic status is inversely related to bed net use in Gabon.Antipyretic effect of ibuprofen in Gabonese children with uncomplicated falciparum malaria: a randomized, double-blind, placebo-controlled trial.Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria.Prognostic value of circulating pigmented cells in African children with malariaHaplotype specific-sequencing reveals MBL2 association with asymptomatic Plasmodium falciparum infection.Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection.Community-acquired pneumonia in children in Lambarene, Gabon.Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon.A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.Antibodies to Plasmodium falciparum rifin proteins are associated with rapid parasite clearance and asymptomatic infectionsIncreased prevalence of intestinal helminth infection during pregnancy in a Sub-Saharan African community.A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals.Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon.Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro.
P50
Q24680404-34D70BE8-0050-4A9E-B7E4-764E6869F3A3Q28278852-734B4BBD-B478-496A-A026-80AEE14F0AC4Q28552379-4A220A3A-5E8A-4B5C-A989-399DB74B1C25Q30402690-28104A6E-B550-456D-85EC-D4E96ABBD344Q30985008-63D7FD0E-3AC1-4617-A42F-FE4408B03C1BQ33512921-4D1F90BC-1D60-4995-A0DE-D36EB78B8452Q33935493-789261C3-6CE9-495E-A9B4-37A407941592Q33987686-B7AC2B55-F8E2-4D84-8C92-356DE06AD6FCQ34039470-2CF40A0F-8139-4438-9C09-BA989837AD86Q34202910-2FF9F805-5ED1-49CE-B796-A48153E0481EQ34300140-93965C09-5EBE-4DD8-8D25-B96732A5DA94Q34551137-8089CD0F-D8C9-4759-B681-B0B39BF219C3Q34734703-224BD14A-8B03-425A-9CCE-7C7F23FCFE6FQ35003450-A48D678E-C5E9-4C3F-B32D-363A38C46313Q35038632-AC4653AB-6438-4267-9BB3-9C52ADB6C6ADQ35645341-97C852AF-7414-453B-91F5-652383C95440Q35751348-170242E1-5B14-470A-855B-878E3E85E753Q35759028-D24B5DB1-D749-4845-B39C-12FE0271FDB2Q35761615-63257D87-48EA-43AC-AB6C-741EF740F9D6Q35827921-26A9E2B0-9672-43AF-92AB-6F0137D9AD19Q36018719-A8397FDA-25BC-4EC2-847F-6C796D411BE2Q36117526-1D55BF47-A6F1-4419-AC3F-70163A34CF3AQ36606694-63A8A829-BFF4-4F27-8F95-F0CFF88A422FQ36693763-08D61DC6-1A26-4B1E-A642-384E4368FA5BQ36981978-FADC0B35-7BD4-4E47-8804-4A414AAEAD19Q37071264-8EBAE6C4-9FF4-427F-A79D-F85DD7139EECQ37127577-51188D6C-A3EE-42E3-AE21-CBC9D93CE93AQ37209510-3D43E435-7870-4F7F-8EC0-32B3B7EAA820Q37600130-C8A72E25-1E01-4D4B-B023-578B7FF4F97AQ37713038-33EE5003-A244-4143-87AE-2C43181B8DE9Q37857108-42B590F7-A193-4125-A2DB-561D0E89A586Q38393755-F7BB7C46-6937-4D00-81F8-D8A5B393FE85Q38500810-1891FFE6-9AFD-48D7-AD6C-9932DE005F18Q38818196-46903E4A-C444-4FF0-9828-985D7ACABC55Q38853596-AA55D90C-2F81-41F3-A07E-D9635CDCFF23Q38854878-B399A660-627A-4B8F-A09F-6C95FA3E9492Q38860337-6D36C540-F2A6-44DA-8AF7-6154C5EF31F7Q38864802-BAB614E6-E76B-46E0-B34B-9CDB72CFDA27Q38918039-C232371C-984C-4BC3-9C6B-653FEFC539EDQ38926366-03CD5C97-5B67-494A-A60D-59FCF06B5484
P50
name
Saadou Issifou
@en
type
label
Saadou Issifou
@en
prefLabel
Saadou Issifou
@en